DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Walter E. Washington Convention Center

2015 年 06 月 14 日 2:30 下午 - 2015 年 06 月 18 日 6:45 下午

801 Mount Vernon Place, NW, , Washington, DC 20001-3614 , USA

DIA 2015 51st Annual Meeting: Develop. Innovate. Advance.

Full conference and one-day registrants will have access to presentation PDFs through Friday, December 18, 2015 <A href="http://www.diaglobal.org/Flagship-Meetings/DIA-Annual-Meeting/Meeting-Program/ePac-Presentations-Access.aspx">Review Presentations </A>

Pediatric Drug Development

Session Chair(s)

Maureen  Smith, MEd

Maureen Smith, MEd

Member

Clinical Trials Ontario College of Lived Experience, Canada

There is greater demand from regulatory and clinical care communities to include pediatric patients in clinical development. However, inclusion of pediatric patients poses unique challenges in preclinical work, clinical trials, and navigation of regulatory processes. The aim of this panel is to describe the challenges and to offer approaches and solutions to help overcome them. We will discuss animal models and drug screening platforms, clinical trial design, unique information needs, and regulatory pathways. Attention will be given to highlighting differences in pediatric orphan drug development and regulatory frameworks in major and emerging geographies.

Learning Objective : Discuss the unique development and regulatory challenges of developing drugs in pediatric rare disease patients; Describe approaches and solutions to overcome these challenges.

Speaker(s)

Shu-Wha  Lin

Preclinical and Clinical Drug Development in Juvenile Rare Diseases

Shu-Wha Lin

National Taiwan University College of Medicine , Taiwan

Professor, Department of Laboratory Science Medical Biotechnology

Dinah  Duarte, MSc

Regulatory Framework in Pediatric Rare Diseases

Dinah Duarte, MSc

European Medicines Agency, Netherlands

Signal Management Lead

注册方法

Registration override should work.

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。